|
1
|
WHO-EORTC classification for cutaneous lymphomas.
|
Blood
|
2005
|
12.14
|
|
2
|
Improved overall survival in melanoma with combined dabrafenib and trametinib.
|
N Engl J Med
|
2014
|
5.65
|
|
3
|
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
|
Nature
|
2011
|
3.53
|
|
4
|
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
|
Am J Clin Pathol
|
2005
|
2.15
|
|
5
|
Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
|
Arch Dermatol
|
2011
|
2.03
|
|
6
|
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.
|
J Cutan Pathol
|
2005
|
1.51
|
|
7
|
Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma.
|
J Cutan Pathol
|
2008
|
1.50
|
|
8
|
Distinctive features of melanoma and its management in elderly patients: a population-based study in France.
|
JAMA Dermatol
|
2013
|
1.49
|
|
9
|
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
|
Arch Dermatol
|
2008
|
1.47
|
|
10
|
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
|
J Clin Oncol
|
2011
|
1.20
|
|
11
|
Characteristics of the coexistence of melanoma and renal cell carcinoma.
|
Cancer
|
2010
|
1.08
|
|
12
|
The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
|
Am J Clin Dermatol
|
2007
|
1.01
|
|
13
|
Neurolymphomatosis associated with Sézary syndrome.
|
Arch Dermatol
|
2009
|
0.95
|
|
14
|
Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?
|
Am J Surg Pathol
|
2007
|
0.93
|
|
15
|
Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
|
Am J Surg Pathol
|
2016
|
0.86
|
|
16
|
P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas.
|
Eur J Dermatol
|
2006
|
0.84
|
|
17
|
Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
|
J Am Acad Dermatol
|
2012
|
0.82
|
|
18
|
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
|
Br J Cancer
|
2008
|
0.81
|
|
19
|
Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients.
|
Dermatology
|
2014
|
0.79
|
|
20
|
The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France.
|
Arch Dermatol
|
2010
|
0.78
|
|
21
|
Sex-related location of head and neck melanoma strongly argues for a major role of sun exposure in cars and photoprotection by hair.
|
J Invest Dermatol
|
2013
|
0.78
|
|
22
|
Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.
|
Arch Dermatol
|
2009
|
0.77
|
|
23
|
Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.
|
JAMA Dermatol
|
2014
|
0.77
|
|
24
|
Cutaneous lymphomas: what can we learn from location?
|
Arch Dermatol
|
2009
|
0.75
|
|
25
|
Second malignant neoplasm occurring years after hyperthermic isolated limb perfusion for melanoma.
|
Arch Dermatol
|
2010
|
0.75
|
|
26
|
Ethanolic Extract of Algerian Propolis and Galangin Decreased Murine Melanoma T.
|
Anticancer Agents Med Chem
|
2016
|
0.75
|
|
27
|
Long-term survivors in stage IV melanoma: a regional population-based study in France.
|
Eur J Dermatol
|
2008
|
0.75
|
|
28
|
Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
|
Arch Dermatol
|
2009
|
0.75
|
|
29
|
[Conclude that clinical trials on the overall effectiveness of interferon? Contribution of recent data].
|
Ann Dermatol Venereol
|
2011
|
0.75
|
|
30
|
[Therapy algorithm for cutaneous T-cell lymphomas].
|
Ann Dermatol Venereol
|
2005
|
0.75
|
|
31
|
IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type.
|
J Invest Dermatol
|
2010
|
0.75
|